Compositions monovalent for CD28 binding and methods of use

US10919965B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• Domantis Limited · GB

Inventors

• Murray McKinnon · Washington Crossing, US
• Steven G. Nadler · Princeton, US
• Suzanne J. Suchard · Wilmington, US
• Brendan J. Classon · Seattle, US
• Steve Holmes · Cambridge, GB
• Olga Ignatovich · Cambridge, GB
• Christopher Plummer · Flint Mountain, GB
• Steve Grant · Swaffham Prior, GB

Key dates

• Filing date: Jan 12, 2018
• Grant date: Feb 16, 2021
• Expiry date: Oct 16, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.